Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 397

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 397
---
 (27    | ) |     | –         |   |     |      204 |     | (204   | ) |     |        – |     | –      |   |     |         – |     |         – |
| DARA Options                     |     |     138 |     | –      |   |     | –         |   |     |      138 |     |        |   |     |      138 |     | (10    | ) |     |         – |     |       128 |

| * | *Number and original                                                                                                               
 price of warrants have been adjusted to reflect the share consolidation and ratio change of ADS’s to ordinary shares that occurred 
 on 2 March 2020 and 24 March 2023 and the ratio change of ADS’s to ordinary shares on 26 September 2022 and 5 July 2023.           |

| F-59 |

| 19 | Financial instruments – risk management |

The Group is exposed
through its operations to the following financial risks:

| · | Credit risk |

| · | Foreign exchange risk |

| · | Liquidity risk |

This note describes
the Group’s policies and processes for managing those risks. The policy for managing these risks is reviewed and agreed with the
Board, however it has delegated the authority for designing and operating processes that ensure the effective management of the risks
to the Group’s management.

Principal financial
instruments

The principal financial
instruments used by the Group, from which financial instrument risk arises, are as follows:

| · | Trade and other receivables |

| · | Cash and cash equivalents |

| · | Trade and other payables |

| · | Accruals |

| · | Loans and borrowings |

| · | Derivative financial liability |

A summary of the financial
instruments held by category is provided below:

Financial assets
– amortised cost

| Schedule of consolidated derivative financial instruments |     |            |     |            |     |            |
|                                                           |     | 2023 £’000 |     | 2022 £’000 |     | 2021 £’000 |
| Cash and cash equivalents                                 |     |      5,971 |     |      2,836 |     |     10,057 |
| Trade receivables                                         |     |          – |     |        329 |     |         33 |
| Other receivables                                         |     |        282 |